Experimental shot aims to quiet Alzheimer's brain protein
NCT ID NCT05469360
First seen Jun 05, 2026 · Last updated Jun 08, 2026 · Updated 1 time
Summary
This early-stage study tests a single injection of NIO752 into the spinal fluid of 38 adults with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The main goal is to see if the drug safely lowers levels of tau, a protein linked to brain damage. Participants are randomly assigned to receive the drug or a placebo, and neither they nor their doctors know which they got.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kuopio, 70210, Finland
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Valencia, Valencia, 46017, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Malmö, 221 85, Sweden
-
Novartis Investigative Site
Stockholm, 141 86, Sweden
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.